RPS6 and focal segmental glomerulosclerosis: Despite RPS6 not being our target gene, its classification as a hub gene, upregulation in FSGS patients, association with podocyte dysfunction, and positive therapeutic impact on podocyte hypertrophy indicate that ribosomal genes warrant further investigation and may hold promise as a therapeutic target for FSGS.